November 2025 — Monthly Briefing¶

1. What was read¶

874 research articles from 32 of the 33 journals on the roster.

A further 259 records (23% of the 1,133 this month's harvest returned) carry no abstract and are not research: news, correspondence, editor highlights and obituaries. PubMed types them Journal Article and nothing else, so the publication-type filter cannot see them — across the whole index they are 22.7% of it and 35% of general, and 3,801 of them are JAMA. Every count below is over the full harvest and is inflated by this; the figure above is not.

General	Cancer	Immune	Bioinfo	Sysbio
496	173	95	334	35

Volume swing against the median month: sysbio +46%

Check the source before reading anything into this. Two benign causes account for most of these. bioinfo every January carries the Nucleic Acids Research database issue and runs high. And several journals simply deposit nothing in some months: across the 44 months read, 4 of 33 journals are absent from at least one, worst being Nat Mach Intell (20 months missing, 81 papers in total) and Bioinformatics (4 months missing, 2,905 papers in total). This month is missing Nat Mach Intell. Queried directly, PubMed returns zero for those journal-months too — the holes are in the source, reproduced exactly by re-running the harvest. So a swing here is not evidence that a field went quiet, and is not usually evidence that the pipeline broke either.

Largest contributors: Nucleic Acids Res 144, Nature 100, JAMA 98, Science 93, Lancet 56, Bioinformatics 43.

2. Net change on the thread curve¶

Thread	This month	Cumulative	Status
`agentic-ai`	+1	+17 / −3	forming
`cell-therapy`	+5	+201 / −63	forming
`ctdna-mrd`	+1	+72 / −23	forming
`foundation-models`	+4 / −3	+128 / −82	splitting
`immunotherapy-resistance`	+2 / −1	+220 / −82	forming
`interception`	+1	+125 / −23	forming
`method-credibility`	−17	+18 / −476	crisis
`neoantigen-vaccines`	+2 / −1	+79 / −41	splitting
`neuro-immune-microbiome-axis`	+5 / −1	+189 / −20	forming
`next-gen-checkpoints`	−2	+68 / −44	splitting
`single-cell-3d-genome`	+3	+74 / −17	forming
`suppressive-population-inversion`	+1 / −4	+52 / −89	contested

Status is derived by rule, not asserted. Fewer than 5 cards → too-early; then refutes ≥ 2×supports → crisis; refutes > supports → contested; supports ≥ 2×refutes → forming; else splitting.

3. The evidence that moved it¶

Single-cell foundation models and the case against them are in the same two journals in the same month. Three titles carry explicit single-cell foundation-model language. EpiAgent is pretrained on a curated human scATAC corpus and encodes chromatin accessibility as "cell sentences", taking the modality off RNA and handling annotation, imputation, perturbation-response prediction and zero-shot typing. Nature Biotechnology publishes Overcoming barriers to the wide adoption of single-cell large language models, a Comment reporting that scLLMs remain little used in practice, with technical gaps and practical barriers standing between the benchmark studies and the bench. The capability and the adoption gap are stated within weeks of each other by the same publishing apparatus.

Corrected 2026-08-26

An earlier version of this paragraph claimed the vocabulary arrived here for the first time, and that skepticism had led it by about three months. Neither survives the 2025-01..07 backfill. "Virtual cell" was already in a Nature Biotechnology title in April 2025, two months before the Cell challenge that named it, and single-cell foundation models were being evaluated as a class in April and again in June. The vocabulary and its critique have been co-present since spring 2025. What is true of November is narrower and duller: this is when both reached Nature Methods and Nature Biotechnology together. Every "first appearance" claim in this corpus is bounded by which months were searched, and each month's reader searched only its own.

A brain-to-gut circuit, traced end to end. 40841473 (Nature Cancer) reports that colorectal cancer cells hijack a polysynaptic circuit running from GABAergic lateral septum neurons to enteric cholinergic neurons to sustain tumour growth, and that chronic restraint stress potentiates it. A named anatomical route, the transmitter systems at both ends, and a behavioural modifier, in one paper.

Corrected 2026-08-27

This paragraph said two independent groups had described the same circuit in the same issue, citing 40841473 and 41057693 together, and called convergence in one issue "the strongest evidence grade available from literature alone" — the argument that was supposed to separate this thread from the checkpoint thread, where nominations never recur.

41057693 is the Nature Cancer News & Views on 40841473. There is one study here, and its own journal's write-up of it. The thread may still be the healthiest in the file, but this is not the reason: an echo counted as convergence is a worse error than a wrong stance, because a wrong stance argues and an echo only agrees with itself.

PD-1's own logic was questioned. 41299179 (Nature, indexed 2026-01) reports that the inhibitory PD-1 axis maintains high-avidity stem-like CD8 T cells. If sustained PD-1 signalling preserves the pool that checkpoint blockade depends on, then permanent blockade and the entire next-generation-checkpoint design premise need restating.

CAR-T's growth edge is autoimmunity, not solid tumours. Anti-BCMA CAR-T in progressive multiple sclerosis and dual CD19/BCMA co-infusion in refractory lupus are single-arm and small, but the direction is unambiguous and it is why car-t-solid was merged into cell-therapy — the narrower claim could no longer hold the evidence.

4. Refutations¶

(a) Landing on a tracked thread¶

41023479 (Nat Immunol): plasmacytoid dendritic cells are dispensable or detrimental in viral infection. 41191775 (Sci Transl Med): depleting pDCs rescues HIV-reactive stem-like CD8 T cells. The therapeutic direction on a cell type treated for twenty years as a protective interferon source is removal.

Corrected 2026-08-27

41136761, "A co-stimulatory signal via the coinhibitory TIGIT", was listed here as a fresh inversion, on the reading that the receptor's assigned sign had been reversed again, two months after 41094201 and in the same journal.

It was not two months and it was not again. 41136761 is the Nature Immunology front-matter piece accompanying 41094201 in the same issue, and PubMed carries no abstract for it. Both were carded refutes on both of the same two threads. One observation about TIGIT — that a receptor classified as co-inhibitory and pursued as a blockade target carries a tissue-protective function — was counted twice, and the sentence manufactured a recurrence out of the duplication. The observation stands; it is 41094201's.

40924026 (JEM): gut regulatory T cells are required for host disease tolerance in Salmonella superspreaders.

40742298 (Cancer Discov): sucralose consumption ablates immunotherapy response through microbiome disruption. Filed as a refutation on the neuro-immune-microbiome thread, because it removes the assumption that diet is a neutral background in checkpoint trials. If the effect size transfers to humans at dietary doses, it is an uncontrolled variable in every trial the corpus tracks.

(b) Method credibility¶

Seventeen cards, a heavy month but not the largest: 2024-01 holds that at thirty. Two are on genome editing: HDR-enhancing DNA-PKcs inhibition causes large-scale genomic alterations and repair of double-strand breaks leaves heritable impairment to genome function. The second is the more serious: it says the damage survives successful repair, which no editing platform's safety case currently accounts for.

Corrected 2026-09-04

This read "Ten cards, the largest month." Ten was the count when November 2025 was carded from titles; the 2026-09-04 abstract re-scan puts it at seventeen, which is the −17 in section 2. The superlative was never checked against the rest of the corpus: four months that precede this one — 2024-01, 2024-06, 2024-07 and 2025-01 — each carry more than seventeen method-credibility cards, and 2024-01's thirty is the maximum. The count was a fact about how November was read; the superlative was a fact about how forty-three other months had been read, and nobody who wrote it had read them.

39592777 (Nat Biotechnol): standard single-cell batch integration destroys real biological signal. The correction class over-corrects, and every atlas built through it inherits the loss.

40930103 (Cell Genomics): analog epigenetic memory revealed by targeted chromatin editing — DNA methylation holds gene expression at analog levels over time rather than switching it binary.

Corrected 2026-08-27

This entry read as "two independent papers overturning the same binary", the second being 41232507, "The dimmer switch in epigenetics". That record is the Cell Genomics preview of 40930103 in the same issue; its whole abstract is one sentence pointing at it. The binary is overturned once, by the paper that did the chromatin editing.

41193809 (Nature, indexed 2026-01): specificity, length and luck drive gene rankings in association studies.

Retractions: sFRP2 in the aged microenvironment as a driver of melanoma metastasis and therapy resistance, and sponges at the root of the animal tree.

5. Open items¶

Nothing carried forward.

6. Meetings¶

No abstract book published this month. The abstract layer runs 2023-02 to 2026-08 and is seasonal by nature — meetings are annual, so most months are empty here and that is the expected shape, not a gap in the harvest.

7. Regulatory¶

Event	Count
trial-first-posted	390 (of which 345 genuinely oncology)
ema-authorisation	14
fda-approval	10

10 FDA actions — dated from each notice's own prose, not the table's posting date, which disagrees on 7 of 190 rows and once by enough to move an approval into the wrong month:

2025-11-06 — FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma
2025-11-13 — FDA approves new interchangeable biosimilar to Perjeta
2025-11-13 — FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation
2025-11-18 — FDA approves epcoritamab-bysp for follicular lymphoma indications
2025-11-19 — FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer
2025-11-19 — FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
2025-11-19 — FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis
2025-11-19 — FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
2025-11-21 — FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
2025-11-25 — FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma

4 EMA oncology authorisations:

2025-11-17 — Lynkuet
2025-11-17 — Xbonzy
2025-11-17 — Degevma
2025-11-17 — Zvogra

8. Trade press¶

31 on-topic of 288 items across 3 feeds (n-stat 277, n-aacr-blog 8, n-acir 3). Headlines are selected by subject keyword, not recency — most of what these feeds carry is health policy and industry finance the corpus does not read.

2025-11-26 — Opinion: STAT+: What if RFK Jr. reacted to his cousin’s terminal cancer as JFK reacted to his baby’s death? — n-stat
2025-11-25 — STAT+: FDA approves Otsuka kidney disease therapy — n-stat
2025-11-25 — STAT+: Pharmalittle: We’re reading about a Novo next-gen diabetes drug, a Novartis gene therapy, and more — n-stat
2025-11-25 — Opinion: The hidden reason lung cancer screening is not working — n-stat
2025-11-23 — STAT+: Kidney cancer cases spiked in this town. Will residents find out why? — n-stat
2025-11-21 — Editors’ Picks, November 2025: Sucralose’s Effect on Immunotherapy, Benefits of Caloric Restriction on Prostate Cancer Treatment, and More — n-aacr-blog
2025-11-20 — One Size Doesn’t Fit ALL: Dynamic Approaches to Childhood Leukemia — n-aacr-blog
2025-11-20 — STAT+: FDA approves Paradromics’ brain-computer interface trial for speech restoration — n-stat
2025-11-20 — STAT+: Abbott to buy cancer screening test maker Exact Sciences in $21B deal — n-stat
2025-11-19 — STAT+: FDA approval for AI isn’t working. What about medical licenses instead? — n-stat
2025-11-18 — STAT+: FDA’s stronger warning on Sarepta gene therapy raises new questions about heart risk — n-stat
2025-11-17 — A cervical cancer prevention milestone — n-stat
… and 19 more on-topic items.